Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.88, while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $529.65 |
52-Week Low | $37.98 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI, the REX FANG & Innovation Equity Premium Income ETF, trades at $41.88, showing minimal daily movement with a 0.02% gain. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF employs a covered call strategy on a concentrated basket of AI and mega-cap tech stocks, generating a high yield through weekly dividends, with recent payouts around $0.20-$0.21 per share. Recent news highlights its transition to weekly distributions and investor interest due to its aggressive income approach.
FEPI offers a high-yield opportunity through its covered call strategy, appealing for income-focused investors, but faces risks from NAV erosion in downturns and limited upside potential. The concentrated portfolio of volatile tech names increases exposure to sector-specific swings, requiring careful risk assessment for long-term holdings.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
